You are here

Genetic Profiles for Perioperative Applications

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44GM064317-02
Agency Tracking Number: GM064317
Amount: $1,108,626.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
THIRD WAVE TECHNOLOGIES, INC. 506 S ROSA RD
MADISON, WI 53719
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROBERT KWIATKOWSKI
 (608) 273-8933
 BKWIATKOWSKI@TWT.COM
Business Contact
 ROD HISE
Phone: (608) 273-8933
Email: RHISE@TWT.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The objectives of Phase II are to develop, validate, and commercialize a tool for detecting genotypes affecting patient care and safety during the perioperative interval (before, during, and immediately following surgery). Despite publications describing genetic risk factors, genetic screening is not performed before surgery. There is a need and a sizeable potential market for a method to prevent adverse clinical outcomes in surgery patients. This proposal addresses this need by expanding on Phase I to develop a cost-effective system to analyze genomic DNA from blood. This approach relies on the Invader assay, a method for detecting defined genetic variations without PCR. An innovation in Phase II is the "biplex" Invader format allowing simultaneous detection of wild-type and mutant alleles in one well. Our specific aims involve: (1) genotyping 1,200 patient samples from 3 medical centers for 100 alleles using conventional methods; (2) developing biplex Invader assays for the new alleles; (3) formatting the assays for manual and automated analysis; and (4) validating them on patient samples. Successful completion of Phase II will result in a cost-effective panel suitable for point-of-care genotyping and has the potential to engender other innovative uses of genetic information.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government